002589.SHE Shandong Realcan Pharmaceutical Co Ltd
- Market cap
- CNY 4.09B
- P/E
- 272.0x
- P/B
- 0.77x
- ROE
- 0.2%
- Dividend yield
- 4.26%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 002589.SHE undervalued?
Graham numberThe Graham number of Shandong Realcan Pharmaceutical Co Ltd cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Shandong Realcan Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Shandong Realcan Pharmaceutical Co Ltd yet.
Shandong Realcan Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Shandong Realcan Pharmaceutical Co Ltd
Realcan Pharmaceutical Group Co., Ltd. sells medicines, medical devices, and medical consumables to medical institutions in China. It operates through the Drug and Equipment Distribution, In Vitro Diagnostics, Pharmaceutical Logistics, Traditional Chinese Medicine, and Microbiome Medicine segments. The company engages in the processing, manufacture, sale, and wholesale of Chinese medicinal materials, herbal medicine, and patent medicine. It is also involved in the wholesale …
Full company profileShandong Realcan Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Shandong Realcan Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 15.6B | 23.3B | 33.9B | 35.3B | 27.2B | 21.1B | 12.3B | 8.03B | 7.97B | 7.30B | 6.86B |
| Gross Profit | 2.42B | 4.21B | 6.38B | 6.66B | 4.86B | 3.74B | 1.63B | 822M | 871M | 776M | 790M |
| Operating Income | 861M | 1.81B | 1.97B | 130M | 956M | 499M | -1.72B | -127M | 25.5M | 68.2M | 127M |
| EBITDA | 1.06B | 2.23B | 2.95B | 1.29B | 1.92B | 1.36B | -1.02B | 403M | 418M | 361M | 220M |
| Net Income | 591M | 1.01B | 771M | -928M | 261M | 131M | -1.83B | 20.3M | 20.6M | 16.1M | 12.4M |
| EPS | 0.44 | 0.67 | 0.51 | -0.62 | 0.18 | 0.09 | -1.24 | 0.01 | 0.01 | 0.01 | 0.01 |
| Balance Sheet | |||||||||||
| Total Assets | 15.7B | 27.0B | 34.8B | 32.5B | 31.3B | 26.4B | 18.3B | 16.7B | 16.0B | 14.4B | 15.4B |
| Total Liabilities | 8.15B | 17.3B | 23.5B | 22.2B | 21.6B | 16.7B | 12.6B | 11.1B | 10.3B | 8.95B | 9.97B |
| Shareholders' Equity | 6.88B | 7.81B | 8.45B | 7.19B | 7.47B | 7.57B | 5.41B | 5.45B | 5.54B | 5.30B | 5.31B |
| Cash & Short-term Investments | 2.05B | 2.02B | 3.15B | 5.03B | 5.77B | 4.58B | 5.34B | 5.06B | 4.98B | 3.74B | 5.00B |
| Total Debt | 1.92B | 5.33B | 8.62B | 6.57B | 10.1B | 4.27B | 3.92B | 6.82B | 6.42B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | -1.76B | -2.42B | -202M | 2.09B | 415M | 443M | 523M | 82.5M | 160M | 13.8M | - |
| Capital Expenditure | 317M | 385M | 604M | 935M | 505M | 461M | 171M | 298M | 112M | 26.8M | 58.8M |
| Free Cash Flow | -2.08B | -2.81B | -774M | 1.16B | -141M | -18.1M | 352M | -216M | 48.9M | -13.1M | -46.6M |
| Ratios | |||||||||||
| ROE | 8.6% | 12.9% | 9.1% | -12.9% | 3.5% | 1.7% | -33.9% | 0.4% | 0.4% | 0.3% | 0.2% |
| ROA | 3.8% | 3.7% | 2.2% | -2.9% | 0.8% | 0.5% | -10.0% | 0.1% | 0.1% | 0.1% | 0.1% |
| Net Profit Margin | 3.8% | 4.3% | 2.3% | -2.6% | 1.0% | 0.6% | -14.9% | 0.3% | 0.3% | 0.2% | 0.2% |
| Debt to Equity | 0.28x | 0.68x | 1.02x | 0.91x | 1.35x | 0.56x | 0.72x | 1.25x | 1.16x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Shandong Realcan Pharmaceutical Co Ltd dividends
- Dividend yield
- 4.26%
- Forward dividend
- -
- Payout ratio
- 1,085.8%
- Ex-dividend date
- Jun 30, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 174M | 0.12 | 1,085.8% |
| 2024 | CNY 199M | 0.13 | 963.6% |
| 2023 | CNY 202M | 0.13 | 992.7% |
| 2022 | CNY 13.3M | 0.01 | - |
| 2021 | CNY 316M | 0.22 | 241.1% |
| 2020 | CNY 347M | 0.24 | 132.6% |
| 2019 | CNY 500M | 0.33 | - |
| 2018 | CNY 516M | 0.34 | 66.9% |
| 2017 | CNY 224M | 0.15 | 22.2% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 23:10 on May 15, 2017.
Who owns Shandong Realcan Pharmaceutical Co Ltd
- Insiders 30.70%
- Institutions 0.40%
- Public & others 68.90%
- Shares outstanding 1.50B
- Free float 1.04B
Shandong Realcan Pharmaceutical Co Ltd company profile
- Company name
- Shandong Realcan Pharmaceutical Co Ltd
- Ticker
- 002589.SHE
- ISIN
- CNE1000013X5
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Jun 10, 2011
- Sector
- Healthcare
- Industry
- Health Care Providers & Services
- Employees
- 2,407
- Fiscal year end
- December
- Address
- Building 13, Yantai, China, 264001
- Phone
- 86 53 5673 5656
- Website
- realcan.cn
About Shandong Realcan Pharmaceutical Co Ltd
Realcan Pharmaceutical Group Co., Ltd. sells medicines, medical devices, and medical consumables to medical institutions in China. It operates through the Drug and Equipment Distribution, In Vitro Diagnostics, Pharmaceutical Logistics, Traditional Chinese Medicine, and Microbiome Medicine segments. The company engages in the processing, manufacture, sale, and wholesale of Chinese medicinal materials, herbal medicine, and patent medicine. It is also involved in the wholesale of biochemical, psychotropic, narcotic, and toxic drugs for medical use; chemical APIs, and preparations; antibiotics, biological products, anabolic steroids, peptide hormones, and pharmaceutical precursor chemicals; and medical devices. In addition, the company provides leasing of medical devices and technical services; investment management and consulting services; medical sterilization outsourcing and consulting services; health consulting services; and pharmaceutical logistics services. Further, it engages in the warehousing and distribution of drugs; technology development and transfer; and operation of a health service platform. The company was formerly known as Realcan Pharmaceutical Co., Ltd. and changed its name to Realcan Pharmaceutical Group Co., Ltd. in December 2018. Realcan Pharmaceutical Group Co., Ltd. was founded in 2004 and is based in Yantai, China.
Shandong Realcan Pharmaceutical Co Ltd management
5- Mr. Xu HanPresident & Chairman · born 1965
- Ms. Yi FengCFO & VP · born 1970
- Mr. Bo YangVP & Director · born 1983
- Mr. Zhe LiVP, Secretary & Director · born 1986
- Qing Yan CaoAccounting Supervisor